Jennifer Jerome
Family · Vernon, CTNPI 1134661531
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 384 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 36.8% of the total. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$711
- AstraZeneca$580
- Axsome Therapeutics, Inc.$547
- Novo Nordisk$508
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$383
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,56997%
- Education$2413%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 164 | $3,239 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $711 |
| AstraZeneca | 18 | $580 |
| Axsome Therapeutics, Inc. | 18 | $547 |
| Novo Nordisk | 21 | $508 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $383 |
| GSK | 22 | $374 |
| Teva Pharmaceuticals USA, Inc. | 7 | $315 |
| Vanda Pharmaceuticals Inc. | 14 | $231 |
| Boehringer Ingelheim | 5 | $223 |
| Lilly USA, LLC | 9 | $199 |
| Alkermes, Inc. | 8 | $170 |
| Optinose US, Inc. | 8 | $163 |
| Pfizer | 8 | $145 |
| Otsuka America Pharmaceutical, Inc. | 8 | $145 |
| Astellas Pharma US Inc | 3 | $134 |
| Lundbeck LLC | 5 | $92 |
| Amarin Pharma, Inc. | 4 | $79 |
| Avanir Pharmaceuticals, Inc. | 1 | $65 |
| Johnson & Johnson | 3 | $59 |
| Bausch Health US, LLC | 3 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $51 |
| QOL Medical, LLC | 2 | $45 |
| Impel Pharmaceuticals Inc. | 2 | $45 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Corium, LLC | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Abbott | 1 | $20 |
| TMS Neurohealth Centers Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| Ardelyx, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,809 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 11 | $25,773 |
| MounjaroTirzepatide | 12 | $12,856 |
| EliquisApixaban | 16 | $9,401 |
| FarxigaDapagliflozin Propanediol | 12 | $6,865 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $717 |
| Buspirone Hcl | 22 | $392 |
| Escitalopram Oxalate | 30 | $342 |
| Methocarbamol | 12 | $288 |
| Gabapentin | 19 | $208 |
| Tramadol Hcl | 12 | $196 |
| Rosuvastatin Calcium | 35 | $176 |
| Levothyroxine Sodium | 17 | $151 |
| Lorazepam | 22 | $148 |
| Losartan Potassium | 12 | $119 |
| Amlodipine Besylate | 18 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $508 | $25,77311 claims |
| Lilly USA, LLCMounjaro | $199 | $12,85612 claims |
| PfizerEliquis | $145 | $9,40116 claims |
| AstraZenecaFarxiga | $580 | $6,86512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in Vernon
- Susan IzzoVernon$17K
- Jude HallVernon$8K
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.